Table 1.
Baseline patients’ characteristics after propensity score matching.
| Total (N=1238) | High-volume centers (N=619) | Mid-volume centers (N=523) | Low-volume centers (N=96) | P-value | |
|---|---|---|---|---|---|
| Age (years) (mean ± SD) | 44.7 ±10.4 | 44.7 ± 10.3 | 48.4 ± 11.6 | 46.2 ± 10.1 | 0.89 |
|
| |||||
| Pathological stage | 0.41 | ||||
| IB1 | 1145 (92.5%) | 567 (91.6%) | 485 (92.7%) | 93 (96.9%) | |
| IB2 | 68 (5.5%) | 38 (6.1%) | 27 (5.2%) | 3 (3.1%) | |
| IIA1 | 25 (2.0%) | 14 (2.3%) | 11 (2.1%) | 0 | |
|
| |||||
| Histology | 0.18 | ||||
| Squamous | 769 (62.1%) | 383 (61.9%) | 333 (63.7%) | 53 (55.2%) | |
| Adenocarcinoma | 395 (31.9%) | 193 (31.2%) | 168 (32.1%) | 34 (35.4%) | |
| Adenosquamous | 50 (4.0%) | 27 (4.4%) | 16 (3.1%) | 7 (7.3%) | |
| Others | 22 (1.8%) | 16 (2.5%) | 6 (1.2%) | 0 | |
| Unknown | 2 (0.2%) | 0 | 0 | 2 (2.1%) | |
|
| |||||
| Grade | <0.001* | ||||
| 1 | 147 (11.9%) | 27 (4.4%) | 97 (18.5%) | 23 (24.0%) | |
| 2 | 920 (74.3%) | 540 (87.2%) | 334 (63.9%) | 46 (47.9%) | |
| 3 | 171 (13.8%) | 52 (8.4%) | 92 (17.6%) | 27 (28.1%) | |
|
| |||||
| LVSI | 0.001* | ||||
| No | 593 (47.9%) | 277 (44.7%) | 255 (48.8%) | 61 (63.5%) | |
| Yes | 345 (27.9%) | 169 (27.3%) | 159 (30.4%) | 17 (17.7%) | |
| Unknown | 300 (24.2%) | 173 (27.9%) | 109 (20.8%) | 18 (18.8%) | |
|
| |||||
| Diameter (mm) | 0.77 | ||||
| (mean ± SD) | 20.4±11.9 | 20.2 ± 12.1 | 20.6 ± 11.7 | 19.8 ± 11.1 | |
|
| |||||
| Diameter | 0.68 | ||||
| ≤ 20 mm | 761 (61.5%) | 379 (61.2%) | 319 (61.0%) | 63 (65.6%) | |
| > 20 mm | 477 (38.5%) | 240 (38.8%) | 204 (39.0%) | 33 (34.4%) | |
|
| |||||
| Surgical Approach | 0.12 | ||||
| Open | 885 (71.5%) | 429 (69.3%) | 390 (74.6%) | 66 (68.8%) | |
| Others | 353 (28.5%) | 190 (30.7%) | 133 (25.4%) | 30 (31.2%) | |
|
| |||||
| Adjuvant therapy | 0.62 | ||||
| No | 1124 (90.8%) | 557 (90.0%) | 479 (91.6%) | 88 (91.7%) | |
| Yes | 114 (9.2%) | 62 (10.0%) | 44 (8.4%) | 8 (8.3%) | |
*
p<0.05